(A) Structure of a peptide corresponding to the BIM BH3 domain (blue) bound to MCL-1 (grey; PDB: 2NL9) overlayed with S63845 (cyan) from a structure of it in complex with MCL-1 (PDB: 5LOF). (B) Close-up of how S63845 (cyan) engages the p2 and p4 pockets of MCL-1 (grey; PDB: 5LOF). Note the interaction at p2 is somewhat different to that of ABT-737 and Venetoclax (see Figure 1E,F). This is further illustrated in (C) showing an overlay of the BIM BH3 helix (blue) with S63845 (cyan), ABT-737 (pink) and Venetoclax (yellow). (D) Schematic illustrating AZD0466 consisting of Starpharma's polylysine dendrimer and AstraZeneca's BCL-XL/BCL-2 dual inhibitor, AZD4320. (E) Chemical structure of the DT2116 PROTAC targeting BCL-XL.